• Vaccine Name: SL3261-L. donovani
• Target Pathogen: Leishmania donovani
• Target Disease: Visceral leishmaniasis
• Vaccine Ontology ID: VO_0004672
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Host Species as Laboratory Animal Model: mouse
• KMP-11 gene engineering:
  • Type: Recombinant vector construction
  • Description: The sequence encoding cholera toxin B subunit signal peptide was followed by SpeI/BglII sites for in frame directional cloning of ORF of interest fused with downstream sequences coding for a hemagglutinin epitope (HA)-tag and the transporter domain of AIDA (Schroeder et al., 2011)
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001031
  • Description: (Schroeder et al., 2011)
• Preparation: Five chosen antigens were differentially expressed on the surface or in the cytosol of Salmonella typhimurium SL3261. A two-step procedure was developed to select optimal Salmonella vaccine strains for each antigen, based on bacterial fitness and antigen expression levels (Schroeder et al., 2011).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Mice were vaccinated with a single dose of Salmonella vaccine strains, the carrier control SL3261 or treated with PBS (Schroeder et al., 2011).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: Mice were subsequently challenged with 2×10^6 late-stationary phase L. major promastigotes into the left hind footpad (Schroeder et al., 2011).
• Efficacy: The vaccine strains of Salmonella expressing the novel Leishmania antigens LinJ08.1190 and LinJ23.0410 significantly reduced visceralisation of L. major and enhanced systemic resistance against L. donovani in susceptible BALB/c mice. The results show that Salmonella are valid vaccine carriers for inducing resistance against visceral leishmaniasis but that their use may not be suitable for all antigens (Schroeder et al., 2011).